Boston Scientific won a nod from FDA for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) system. The neuromodulation device can help treat the symptoms of Parkinson’s disease.
The portfolio, approved for conditional use in a magnetic resonance imaging (MRI) environment, consists of a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators (IPGs) that power Cartesia Directional Leads, designed to provide optimal symptom relief.
"We continue to prioritize therapy innovations that improve our patients' quality of life with a wide range of personalized offerings," said Maulik Nanavaty, senior vice president and president, Neuromodulation, Boston Scientific. "For people living with movement disorders, this means developing new technologies that are designed to refine motor control, reduce programming times and expand MR compatibility to improve their treatment experience and ultimately their daily living."
The Marlborough, MA-based company was awarded CE mark for the device in September of 2020.
Medtronic recently made medtech headlines when it launched a trial to evaluate the safety and efficacy of its Percept PC technology using adaptive deep brain stimulation in patients with Parkinson’s Disease.
The Dublin-based company said it enrolled the first patient in the study, which has been dubbed the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD).